DIM
UBX

DC Investments Management’s Unity Biotechnology UBX Stock Holding History

DC Investments Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,604
Closed -$543K – 316
2018
Q2 		$543K Buy
+3,604
New +$527K 0.35% 135

Other funds holding UBX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
NTC
NF Trinity Capital Central, Hong Kong $626M AUM 3.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DC Investments Management's UBX Position: Q3 2018 in Review

DC Investments Management sold out of Unity Biotechnology (UBX) in Q3 2018, closing a stake of 3,604 shares — an estimated $543K sold.

DC Investments Management first reported a position in UBX in Q2 2018 and held it in 1 quarter. The position peaked at $543K in Q2 2018. 42 funds tracked by Wall St. Rank hold UBX as of Q3 2018.

  • DC Investments Management reported no remaining Unity Biotechnology position as of Q3 2018 after selling out during the quarter.
  • DC Investments Management sold 3,604 Unity Biotechnology shares in Q3 2018, an estimated $543K.
  • DC Investments Management first reported a position in Unity Biotechnology in Q2 2018 and held it in 1 quarter.
  • DC Investments Management's Unity Biotechnology position peaked at $543K in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2018.

Based on DC Investments Management's 13F filing for Q3 2018, filed 9 Nov 2018.